Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Inclusion Criteria: * The following criteria must have been met at the initial start of aflibercept treatment (i.e. start of aflibercept treatment at least 1 year before this study): * Subject had primary subfoveal choroidal neovascularization (CNV) lesions secondary to nAMD, including juxtafoveal lesions that affect the fovea, as evidenced by fluorescein angiography/photography (FA/FP) of the study eye within 3 weeks before the initiation of aflibercept treatment. * The area of CNV occupied at least 50% of the total lesion within 3 weeks before the initiation of aflibercept treatment. * Documented best-corrected visual acuity (BCVA) was 20/40 to 20/320 (letter score of 73 to 25) in the study eye at the initiation of treatment. * Men and women \>= 51 years of age * The subject's history of aflibercept treatment meets ALL of the following: * Treatment in the study eye was initiated with three monthly (-1 week/+2 weeks) doses of 2 mg aflibercept and improvements of visual and anatomic outcomes were observed * Following the above initiation phase, the intervals between treatments were between 6 weeks and 12 weeks Exclusion Criteria: \- Any prior or concomitant therapy with an investigational or approved agent to treat neovascular AMD in the study eye other than aflibercept. * Total lesion size \> 12 disc areas (30.5 mm2, including blood, scars and neovascularization) as assessed by fluorescein angiography (FA) in the study eye * Subretinal hemorrhage that was: 1. 50% or more of the total lesion area, or 2. if the blood was under the fovea, and 3. the blood under the fovea was 1 or more disc areas in size in the study eye. * Scar or fibrosis making up more than 50% of the total lesion in the study eye. * Scar, fibrosis, or atrophy involving the center of the fovea in the study eye. * Presence of retinal pigment epithelial tears or rips involving the macula in the study eye. * Causes of CNV other than AMD in the study eye.